Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Assets: 2023-2025

Historic Assets for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $43.3 million.

  • BioLineRx's Assets fell 33.02% to $43.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was $43.3 million, marking a year-over-year decrease of 33.02%. This contributed to the annual value of $38.9 million for FY2024, which is 39.14% down from last year.
  • As of Q2 2025, BioLineRx's Assets stood at $43.3 million, which was down 0.56% from $43.5 million recorded in Q1 2025.
  • In the past 5 years, BioLineRx's Assets ranged from a high of $68.6 million in Q1 2023 and a low of $38.9 million during Q4 2024.
  • Moreover, its 3-year median value for Assets was $52.8 million (2023), whereas its average is $53.9 million.
  • The largest annual percentage gain for BioLineRx's Assets in the last 5 years was 9.60% (2024), contrasted with its biggest fall of 39.14% (2024).
  • Over the past 3 years, BioLineRx's Assets (Quarterly) stood at $63.9 million in 2023, then plummeted by 39.14% to $38.9 million in 2024, then plummeted by 33.02% to $43.3 million in 2025.
  • Its Assets was $43.3 million in Q2 2025, compared to $43.5 million in Q1 2025 and $38.9 million in Q4 2024.